Synthesis, Characterization and In Vitro Anticancer Activity of C-5 Curcumin Analogues with Potential to Inhibit TNF-α-Induced NF-κB Activation

Table 1

Inhibition of hybrid molecules (3a–3p) on chronic myeloid leukemia (KBM5) and colon cancer (HCT116) cell lines at 5 𝜇M.

Compound	Percentage growth inhibition KBM5	Percentage growth inhibition HCT116	Activity
3a	76.06±1.45	52.71±1.01	High
3b	85.52±0.66	57.88±0.45	High
3c	29.38±2.14	20.36±1.48	Moderate
3d	36.32±4.30	25.17±2.98	Moderate
3e	30.09±3.01	20.85±2.08	Moderate
3f	16.33±4.84	11.32±3.36	Low
3g	8.65±7.12	5.99±4.94	Low
3h	86.76±3.09	60.13±2.14	High
3i	17.67±1.54	12.25±1.07	Low
3j	87.61±3.43	60.72±2.38	High
3k	75.09±2.90	52.04±2.01	High
3l	22.33±3.82	15.48±2.65	Moderate
3m	13.27±2.08	9.20±1.44	Low
3n	23.27±1.84	16.12±1.28	Moderate
3o	10.89±4.25	7.55±2.95	Low
3p	83.63±0.34	57.96±0.24	High
Control	0.00±3.36	0.00±2.33
Curcumin	46.00±1.49	46.87±1.03

Compounds are classified based on potential to inhibit growth of KBM5 cancer cell lines at 5 𝜇M, >60%; high activity, >20%; moderate activity, <20%; low activity.